Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-11-30
2000-11-21
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514258, 514299, 514300, 514303, 514336, 514340, 514341, 514342, 514352, 514357, 514359, 514369, 514370, 514376, 514377, 514380, 514393, 514394, 514413, 514414, 514415, 514416, 514419, 514438, 514444, 514825, 514885, 514866, A61K 4500, A61K 3142, A61K 31425
Patent
active
061503711
ABSTRACT:
A method for preventing or treating autoimmune diseases (excluding type I diabetes) by administering an insulin resistance improving substance as an active ingredient.
REFERENCES:
patent: 4287200 (1981-09-01), Kawamatsu et al.
patent: 4340605 (1982-07-01), Kawamatsu et al.
patent: 4438141 (1984-03-01), Kawamatsu et al.
patent: 4444779 (1984-04-01), Kawamatsu et al.
patent: 4461902 (1984-07-01), Kawamatsu et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4687777 (1987-08-01), Meguro et al.
patent: 4703052 (1987-10-01), Eggler et al.
patent: 4725610 (1988-02-01), Meguro et al.
patent: 4873255 (1989-10-01), Yoshioka et al.
patent: 4897393 (1990-01-01), Iijima et al.
patent: 4897405 (1990-01-01), Alessi et al.
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 4918091 (1990-04-01), Cantello et al.
patent: 4948900 (1990-08-01), Iijima et al.
patent: 5002953 (1991-03-01), Hindley
patent: 5061717 (1991-10-01), Clark et al.
patent: 5120754 (1992-06-01), Clark et al.
patent: 5132317 (1992-07-01), Cantello et al.
patent: 5194443 (1993-03-01), Hindley
patent: 5223522 (1993-06-01), Clark et al.
patent: 5232925 (1993-08-01), Hindley
patent: 5260445 (1993-11-01), Hindley
patent: 5550166 (1996-08-01), Ostlund et al.
patent: 5594015 (1997-01-01), Kurtz et al.
patent: 5866595 (1999-02-01), Pershadsingh et al.
Chemical Abstract 97:156763, "Therapeutic Effects of of Dehydroepiandrosterone (DHEA) in Diabetic Mice", Sep. 1982.
Konnichinochiryoushishin, Igaku Shoin, p. 577 (1996) (Collagen Diseases (Connective Tissue Diseases))*.
Byourigakutaikei, Suppl. 1, pp. 91-105 (1995) (Immunotoxicity and Autoimmunity)*.
Tounyoubyou, vol. 37, No. 2, pp. 127-129 (1994) (Study of Inhibition of the Onset of Type I Diabetes By CS-045)*.
N. Yagi et al., "Expression of Intercellular Adhesion Molecule 1 on Pancreatic .beta.-Cell Accelarates .beta.-Cell Destruction by Cytotoxic T-Cells in Murine Autoimmune Diabetes", Diabetes, 44, 744-752 (1995).
J.L. Baron et al., "The Pathogenesis of Adoptive Murine Autoimmune Diabetes Requirea An Interaction Between .alpha.4-Integrins and Vascular Cell Adhesion Molecule-1", J. Clin. Invest., 93, 1700-1708 (1994).
T. Fujiwara et al., "Characterization of New Oral Anidiabetic Agent CS-045", Diabetes, 37, 1549-1558 (1988).
C. Hofmann and J.R. Colca, "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers", Diabetic Care, 15, 1075-1078 (1992).
C.V. Winder et al., "Comparative Bioassays of Drugs in Adjuvant-Induced Arthritis in Rats: Flufenamic Acid, Mefenamic Acid and Phenylbutazone", Arthritis and Rheumatism, 12, 472-482 (1969).
Fujita Takashi
Fujiwara Toshihiko
Fukushige Junichiro
Horikoshi Hiroyoshi
Hosokawa Tsunemichi
Krass Frederick
Sankyo Company Limited
LandOfFree
Method for preventing and for treating autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing and for treating autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing and for treating autoimmune disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1257463